{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:09:01Z","timestamp":1761664141901,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.pep.2020.105752","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T08:57:41Z","timestamp":1600246661000},"page":"105752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Affinity purification of human alpha galactosidase utilizing a novel small molecule biomimetic of alpha-D-galactose"],"prefix":"10.1016","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-0557","authenticated-orcid":false,"given":"Brian","family":"Dwyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameya","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7407-8677","authenticated-orcid":false,"given":"Muthuraman","family":"Meiyappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pep.2020.105752_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry outcome survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.pep.2020.105752_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","article-title":"Prevalence of symptoms in female Fabry disease patients: a case-control survey","volume":"35","author":"Bouwman","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.pep.2020.105752_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pep.2020.105752_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.pep.2020.105752_bib5","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","article-title":"Catalytic mechanism of human alpha-galactosidase","volume":"285","author":"Guce","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pep.2020.105752_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease - current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genom."},{"key":"10.1016\/j.pep.2020.105752_bib7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human alpha-galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.pep.2020.105752_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.pep.2020.105752_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pep.2020.105752_bib10","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.pep.2020.105752_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human alpha-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.pep.2020.105752_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"A review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pep.2020.105752_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2018.02.021","article-title":"Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ","volume":"481","author":"Ferri","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.pep.2020.105752_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800397","article-title":"Affinity chromatography: an enabling technology for large-scale bioprocessing","volume":"15","author":"Lacki","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.pep.2020.105752_bib15","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1016\/j.vaccine.2018.02.090","article-title":"Affinity chromatography for vaccines manufacturing: finally ready for prime time?","volume":"37","author":"Zhao","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.pep.2020.105752_bib16","doi-asserted-by":"crossref","first-page":"105589","DOI":"10.1016\/j.pep.2020.105589","article-title":"Expression, purification, and characterization of human mannose-6-phosphate receptor - extra cellular domain from a stable cell line utilizing a small molecule biomimetic of the mannose-6-phosphate moiety","volume":"170","author":"Dwyer","year":"2020","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2020.105752_bib17","doi-asserted-by":"crossref","first-page":"312709","DOI":"10.1155\/2013\/312709","article-title":"Preparative purification of recombinant proteins: current status and future trends","volume":"2013","author":"Saraswat","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pep.2020.105752_bib18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0021-9258(19)69965-5","article-title":"Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms","volume":"256","author":"Bishop","year":"1981","journal-title":"J. Biol. Chem."}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592820303430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592820303430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:53:59Z","timestamp":1760925239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592820303430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"alternative-id":["S1046592820303430"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2020.105752","relation":{},"ISSN":["1046-5928"],"issn-type":[{"type":"print","value":"1046-5928"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Affinity purification of human alpha galactosidase utilizing a novel small molecule biomimetic of alpha-D-galactose","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2020.105752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105752"}}